title: Abrupt development of sarcoidosis with a prodromal increase in plasma osteopontin in a patient with rheumatoid arthritis during treatment with etanercept.
authors.forename: Shino
authors.initials: S
authors.lastname: Takatori
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Kamata
authors.forename: Takamasa
authors.initials: T
authors.lastname: Murosaki
authors.forename: Masahiro
authors.initials: M
authors.lastname: Iwamoto
authors.forename: Seiji
authors.initials: S
authors.lastname: Minota
mesh_terms: D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000188:drug therapy; D003937:Diagnosis, Differential; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D053495:Osteopontin / Q000097:blood*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D012507:Sarcoidosis / Q000097:blood* / Q000139:chemically induced* / Q000473:pathology
chemical_list: D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D053495:Osteopontin; D000068800:Etanercept